Candela Ceballos is a hematologist and physician-scientist currently working as a postdoctoral visiting investigator at Memorial Sloan Kettering Cancer Center. She completed her training in Hematology and Hemotherapy at the University Hospital of Navarra and subsequently obtained a PhD from the University of Navarra, focused on the development and optimization of CAR T-cell therapies for acute myeloid leukemia.
Before joining MSK, she worked as an attending hematologist at Donostia University Hospital in the allogeneic hematopoietic stem cell transplantation program.
Her research interests focus on the role of host immune and inflammatory states in cancer, hematopoietic stem cell transplantation, and cellular therapies, and their association with treatment outcomes and toxicity.
Paviglianiti A, Perez Lopez E, Avendaño A, Baile M, *Ceballos C, et al. Real-World Validation of the Transplant Conditioning Intensity (TCI) Score in Allogeneic Hematopoietic Cell Transplantation: A Spanish Multicenter Study on behalf of GETH-TC. *Transplant Cell Ther. 2026;32(8):990.e1-990.e8. doi: 10.1016/j.jtct.2026.04.036.
Bailén R, Peña-Muñoz F, Bermúdez A, López-Corral L, *Ceballos C, et al. Spanish Real-World Experience with Belumosudil for Chronic Graft-versus-Host Disease after 2 or More Prior Lines of Therapy. *Transplant Cell Ther. 2026;32(7):864.e1-864.e12. doi: 10.1016/j.jtct.2026.03.001.
Paviglianiti A, Ljungman P, de la Camara R, Tridello G, *Ceballos C, et al. Maribavir for clinically significant cytomegalovirus infection in haematopoietic cell transplant recipients in Europe: a real-world multicentre retrospective registry study. *Lancet Infect Dis. 2026. doi: 10.1016/S1473-3099(26)00144-1.
Diez B, Calviño C, Fernández-García M, Rodríguez-Márquez P, Rodríguez-Díaz S, Martínez-Turillas R, *Ceballos C, et al. Generation and GMP scale-up of human CAR-T cells using non-viral Sleeping Beauty transposons for B cell malignancies. *Mol Ther Methods Clin Dev. 2025;33(1):101425. doi: 10.1016/j.omtm.2025.101425.
Calviño C, *Ceballos C, Alfonso A, Jauregui P, Calleja-Cervantes ME, San Martin-Uriz P, et al. Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia. *Front Immunol. 2023;14:1270843. doi: 10.3389/fimmu.2023.1270843.
Rodriguez-Marquez P, Calleja-Cervantes ME, Serrano G, Oliver-Caldes A, *Ceballos C, et al. CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome. *Sci Adv. 2022;8(39):eabo0514. doi: 10.1126/sciadv.abo0514.
*Ceballos C, Alburquerque C, Zabalza A, Quispe I, Panizo Á, Burguete Y, Redondo AM, Mateos MC. Concomitant lymphoplasmacytic lymphoma, multiple myeloma, and amyloidosis: A diagnostic and therapeutic challenge. *Clin Case Rep. 2022;10(4):e05769. doi: 10.1002/ccr3.5769.